IDEAYA eyes March data readout with $1B cash buffer
IDEAYA Biosciences (NASDAQ:IDYA) reported fourth-quarter and full-year 2025 results on Tuesday, setting a definitive timeline for a high-stakes clinical readout that could transition the precision medicine firm into a commercial-stage biotech.
The South San Francisco-based company confirmed that the requisite 130 Progression-Free Survival (PFS) events have been reached in its OptimUM-02 trial.
The registrational Phase 2/3 study is evaluating the combination of darovasertib and crizotinib in patients with first-line HLA*A2-negative metastatic uveal melanoma.
Topline results are now expected by the last week of March 2026, a milestone investors view as the primary catalyst for a potential accelerated approval filing with the FDA.
In an industry often plagued by capital crunches, IDEAYA reported a formidable financial position, ending 2025 with $1.05 billion in cash, cash equivalents, and marketable securities.
Bolstered by a $210 million upfront payment from its 2025 licensing deal with Servier, the company reaffirmed that its current war chest is sufficient to fund operations into 2030.
More from United States
Lamar raises 2026 AFFO outlook to $8.97
Lemonade posts $336 million Q3 revenue, narrows loss
BD reveals $5.27 billion Q4 revenue, raises 2027 outlook
Cummins earnings surge to $1.14 billion as sales climb 13%
Six Flags reveals $1.17 billion Q3 revenue amid $366 million loss
EPAM Systems reports $1.43B Q3 revenue, expands buyback to $1.8B
